Developing and commercializing first-in-class, well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies.

Eiger BioPharmaceuticals Announces Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients

- Data Safety Monitoring Board recommends continuation of Peginterferon Lambda - Interim analysis of 453 patients, randomized 1:1 Peginterferon Lambda vs placebo PALO ALTO, Calif., Sept. 20, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical

Eiger BioPharmaceuticals to Participate in Upcoming September 2021 Investor Conferences

PALO ALTO, Calif. , Sept. 1, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory , President

Eiger BioPharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

- HDV Platform Strategy Rapidly Advancing - Phase 3 HDV D-LIVR (Lonafarnib) >90% Enrolled; On-Track for Full Enrollment in 2021 - Phase 3 HDV LIMT-2 (Lambda) On-Track for First Patient to Enroll in 2021 - All Five Rare Disease Programs Now Have Breakthrough Therapy Designation - Company to Host